Education
About Us
Working with TipRanks
Follow Us
Quoin Pharmaceuticals (QNRX)
NASDAQ:QNRX
QNRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.01 - $54.95
Previous CloseN/A
Volume155.80K
Average Volume (3M)88.47K
Market Cap
$4.59M
Enterprise Value-$7.64M
Total Cash (Recent Filing)$1.67M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.14
Next Earnings
Nov 06, 2025EPS Estimate
-4.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.28
Shares Outstanding588,167
10 Day Avg. Volume24,231
30 Day Avg. Volume88,475
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap-1.66
Enterprise Value/Revenue-76.07
Enterprise Value/Gross Profit302.04
Enterprise Value/Ebitda0.61
Forecast
1Y Price Target
$70.00Price Target Upside757.84% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentQuoin is continuing to progress the development of QRX003 for treating Netherton Syndrome, with two whole body studies being conducted for regulatory submissions.
Market PotentialNetherton Syndrome remains a very difficult to treat disease with no approved disease-modifying therapeutic options, thus an approved therapy has significant market potential.
Regulatory ProgressThe FDA has granted QRX003 Rare Pediatric Disease Designation, which can expedite its review process and increase the likelihood of approval.
Bears Say
Clinical TrialsQuoin received FDA clearance to initiate a second Whole Body study which will enroll 12-15 patients, and these studies may be evaluated as a pivotal trial since it is most reflective of real-world use.
Regulatory ChallengesIf approved, Quoin may be eligible to receive a Pediatric Review Voucher which can potentially be sold for over $100M, providing nondilutive financing.
Quoin Pharmaceuticals News
QNRX FAQ
What was Quoin Pharmaceuticals’s price range in the past 12 months?
Quoin Pharmaceuticals lowest stock price was $5.01 and its highest was $54.95 in the past 12 months.
What is Quoin Pharmaceuticals’s market cap?
Quoin Pharmaceuticals’s market cap is $4.59M.
When is Quoin Pharmaceuticals’s upcoming earnings report date?
Quoin Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 27 days.
How were Quoin Pharmaceuticals’s earnings last quarter?
Quoin Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$6.28 earnings per share for the quarter, beating the consensus estimate of -$6.82 by $0.54.
Is Quoin Pharmaceuticals overvalued?
According to Wall Street analysts Quoin Pharmaceuticals’s price is currently Undervalued.
Does Quoin Pharmaceuticals pay dividends?
Quoin Pharmaceuticals does not currently pay dividends.
What is Quoin Pharmaceuticals’s EPS estimate?
Quoin Pharmaceuticals’s EPS estimate is -4.29.
How many shares outstanding does Quoin Pharmaceuticals have?
Quoin Pharmaceuticals has 588,167 shares outstanding.
What happened to Quoin Pharmaceuticals’s price movement after its last earnings report?
Quoin Pharmaceuticals reported an EPS of -$6.28 in its last earnings report, beating expectations of -$6.82. Following the earnings report the stock price went down -6.242%.
Which hedge fund is a major shareholder of Quoin Pharmaceuticals?
Currently, no hedge funds are holding shares in QNRX
Company Description
Quoin Pharmaceuticals
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
QNRX Stock 12 Month Forecast
Average Price Target
$70.00
▲(757.84% Upside)
Technical Analysis
Palisade Bio
―
Galmed Pharmaceuticals
―
InMed Pharmaceuticals
―
Artelo Biosciences
―
Galecto
―
Ownership Overview
17.79% Insiders
15.24% Other Institutional Investors
66.96% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---